IAM

Strong SellSinker

Iambic Therapeutics, Inc. · Healthcare · United States · $676M cap

$14.41 +1.1% · close 26 Oct · scored 27 Oct

Sinker: Weak, expensive and falling. Nothing here to keep it afloat.

9
StockRank
Get score and insider alerts
Quality
33
Value
24
Momentum
25

As of 27 Oct 2026, MoatMap's StockRank for Iambic Therapeutics, Inc. (IAM) is 9/100, ranked against 24,000+ stocks in 35 markets (Quality 33, Value 24, Momentum 25, each scored against its sector).

Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →

P/E (TTM)
—
peers 27.2x
ROE
—
peers -30.2%
D/E
0.0x
peers 0.2x
Dividend %
—
trailing yield
Loading 1Y...
PRICE (1Y) · USD-23.8%
14.316.619.021.423.815 Oct21 Oct26 Oct

Price checkNo read yetExperimental

Not enough steady price history for a read yet.

How this is worked out

StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.

The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$14.41

SCORE BREAKDOWN

Quality
33
ROIC (ROA)
—N/A
ROE
—N/A
GP/Assets
—N/A
Op. Margin
-419.6%10.6
FCF/Assets
—N/A
Piotroski
238.6
Int. Cover
—N/A
D/E Ratio
0.03x75.8
Current Ratio
4.59x70.0
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-5.3x25.0
P/FCF
—N/A
P/B
-1.4x25.0
P/S
37.0x10.0
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$676M
P/E (Forward)
—
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IAM are excluded.

TickerCompanyMkt CapStockRankSignal
IAMIambic Therapeutics, Inc.(you)$676M9Strong Sell
ATTOAttovia Therapeutics, Inc.$631M9Strong Sell
ANNXAnnexon, Inc.$711M7Strong Sell
SANASana Biotechnology, Inc.$698M5Strong Sell
OLMAOlema Pharmaceuticals, Inc.$561M10Strong Sell
950260.KQIngenia Therapeutics Inc.$808M11Strong Sell
ETRAElectra Therapeutics, Inc.$547M10Strong Sell
PRMEPrime Medicine, Inc.$666M4Strong Sell
DSGNDesign Therapeutics, Inc.$641M14Strong Sell
ODTXOdyssey Therapeutics, Inc.$942M9Strong Sell

Peer medians: ROE -30.2% · P/E 27.2x · Gross margin 63.3%

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

Iambic Therapeutics, Inc. (IAM): Stock Score Summary

Iambic Therapeutics, Inc. (IAM) has a MoatMap StockRank of 9/100 based on Quality (33/100), Value (24/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price$14.41
Market Cap$676M
Price/Book-1.45
Debt/Equity0.03x
Operating Margin-419.6%
Revenue Growth224.7%

Iambic Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Iambic Therapeutics, Inc.’s (IAM) StockRank?
MoatMap’s StockRank for Iambic Therapeutics, Inc. (IAM) is 9/100, with a Strong Sell signal. It is a composite of Quality (33), Value (24), and Momentum (25), each scored against its sector. The composite is then ranked across MoatMap’s universe of 24,000+ stocks.
Does Iambic Therapeutics, Inc. have an economic moat?
Iambic Therapeutics, Inc. (IAM) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Iambic Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Iambic Therapeutics, Inc. (IAM) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Iambic Therapeutics, Inc. in?
Iambic Therapeutics, Inc. (IAM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).